All In Biotech

Drug Trial Radar · NCT04322006

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

A Phase I/II Study of Evaluating the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Curative Effect of Dose Escalation and Extension for Single Drug TJ004309 and Toripalimab Combine Treatment for Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

225

Actual

Start

May 9, 2020

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
TJ Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to confirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safety, effectiveness, Pharmacokinetics, pharmacodynamics and biomarker properties for effective subjects.

Conditions

  • Advanced Solid Tumor

Interventions

  • TJ004309Drug

    Antibody to CD73

  • ToripalimabDrug

    Humanized monoclonal antibody to PD-1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities(DLT)Time frame: 28days after first dose for QW, 21days after first dose for Q3W
  2. MTDTime frame: 2 years
  3. MEDTime frame: 2 years
  4. Recommend dose of TJ004309Time frame: 2 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Army Medical Center of PLA

    Chongqing, Chongqing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Guangdong Provincial Hospital of Chinese Medicine

    Guangzhou, Guangdong, China

  • Cancer Hospital affiliated to Shantou University Medical College

    Shantou, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi'an, Shaanxi, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hanzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.